Lantheus (NASDAQ:LNTH) Receives “Market Outperform” Rating from Citizens Jmp

Lantheus (NASDAQ:LNTH)‘s stock had its “market outperform” rating restated by equities research analysts at Citizens Jmp in a research note issued to investors on Monday,Benzinga reports. They presently have a $115.00 price objective on the medical equipment provider’s stock. Citizens Jmp’s target price indicates a potential upside of 4.74% from the stock’s current price.

LNTH has been the topic of a number of other research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Lantheus in a research note on Tuesday, May 26th. B. Riley Financial reissued a “buy” rating on shares of Lantheus in a research note on Friday, May 1st. William Blair restated an “outperform” rating on shares of Lantheus in a report on Tuesday, March 17th. Wall Street Zen lowered shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $110.00 price target on shares of Lantheus in a research note on Tuesday, March 17th. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $101.86.

Lantheus Stock Performance

Shares of LNTH stock opened at $109.80 on Monday. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47. Lantheus has a 12 month low of $47.25 and a 12 month high of $111.46. The company’s fifty day simple moving average is $95.88 and its 200-day simple moving average is $80.00. The firm has a market cap of $7.15 billion, a PE ratio of 26.46 and a beta of -0.03.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The company had revenue of $377.33 million during the quarter, compared to analysts’ expectations of $354.48 million. During the same quarter last year, the company earned $1.53 EPS. Lantheus’s revenue for the quarter was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities research analysts expect that Lantheus will post 4.49 EPS for the current fiscal year.

Institutional Investors Weigh In On Lantheus

A number of large investors have recently added to or reduced their stakes in the stock. Western Wealth Management LLC bought a new stake in shares of Lantheus during the 1st quarter valued at $25,000. Smartleaf Asset Management LLC lifted its position in Lantheus by 63.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 197 shares during the period. Parallel Advisors LLC lifted its position in Lantheus by 122.6% during the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 298 shares during the period. Osterweis Capital Management Inc. acquired a new stake in Lantheus during the second quarter worth about $36,000. Finally, Bessemer Group Inc. grew its stake in Lantheus by 221.2% during the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 354 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.